Related references
Note: Only part of the references are listed.More bang for your buck: Improved use of GPU nodes for GROMACS 2018
Carsten Kutzner et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer
E. Fiegle et al.
NEOPLASIA (2019)
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
Houda Bahig et al.
BMC CANCER (2019)
A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
Jung-Yun Lee et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Anti-CTLA-4 therapy requires an Fc domain for efficacy
Jessica R. Ingram et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Fei Tang et al.
CELL AND BIOSCIENCE (2018)
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
Jean-David Fumet et al.
ESMO OPEN (2018)
Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen
Mohammadreza Movahedin et al.
GLYCOBIOLOGY (2017)
doGlycans-Tools for Preparing Carbohydrate Structures for Atomistic Simulations of Glycoproteins, Glycolipids, and Carbohydrate Polymers for GROMACS
Reinis Danne et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)
Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1
Dong Li et al.
MABS (2017)
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
Udupi A. Ramagopal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
Mengnan He et al.
ONCOTARGET (2017)
Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors
Diluka Peiris et al.
SCIENTIFIC REPORTS (2017)
CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field
Jumin Lee et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2016)
Immune checkpoint inhibitors for cancer treatment
Junsik Park et al.
ARCHIVES OF PHARMACAL RESEARCH (2016)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Scott Antonia et al.
LANCET ONCOLOGY (2016)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry
Lei Zhu et al.
MABS (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
COCOMAPS: a web application to analyze and visualize contacts at the interface of biomolecular complexes
Anna Vangone et al.
BIOINFORMATICS (2011)
Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering
Chao Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping
Jacob Bongers et al.
JOURNAL OF CHROMATOGRAPHY A (2011)
Accelerating Protein Docking in ZDOCK Using an Advanced 3D Convolution Library
Brian G. Pierce et al.
PLOS ONE (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
Share Paper
